**A phase 1/2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms**

Edward Wolin,1\* Alain Mita,1 Amit Mahipal,2 Tim Meyer,3 Johanna Bendell,4 John Nemunaitis,5\*\* Pam N Munster,6 Luis Paz-Ares,7 Ellen H Filvaroff,8 Shaoyi Li,9 Kristen Hege,8 Hans de Haan,8 and Monica Mita1

1Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2Phase 1 Clinical Trials Program, Mayo Clinic, Rochester, MN, USA; 3Experimental Cancer Medicine, University College Hospital, London, UK; 4GI Oncology Research, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; 5Department of Oncology,MaryCrowley Cancer Research Center, Dallas, TX, USA; 6Early Phase Clinical Research Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; 7Medical Oncology Department, Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense and CiberOnc, Madrid, Spain; 8Translational Medicine, Celgene Corporation, San Francisco, CA, USA; 9Statistics, Celgene Corporation, Summit, NJ, USA

\*Affiliation at the time the study was conducted. Currently at Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA

\*\*Affiliation at the time the study was conducted. Currently at University of Toledo, College of Medicine and Life Sciences, Ruppert Health Center, Toledo, OH, USA

# Supporting Information

## Checklist S1. CONSORT checklist.

## Protocol S1. Trial protocol.

## Figure S1. CONSORT diagram.

##

## Figure S2. CC-223 dose adjustments and duration, best overall RECIST version 1.1 and target lesion response, and carcinoid symptom improvement, for patients started at 45 mg/day (A) and 30 mg/day (B) CC-223.

Cycle, total treatment cycles completed; RECIST, best overall response; TL change (%), best target lesion change from baseline.

★, carcinoid symptomatic improvement; NE, not evaluable; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria In Solid Tumors; SD, stable disease.

****

****